Search results
Results from the WOW.Com Content Network
Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock. Glaxo (GSK) Shares Continue to Witness Upside ...
Shares of Glaxo (GSK) lag the industry in a year as generic erosion of some drugs mainly its top-selling drug, Advair offsets strong sales of new drugs.
Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven third-quarter sales. Although sales of vaccines are likely to have recovered, the impact of the COVID-19 vaccine ...
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
Glaxo (GSK) beats on earnings and sales in the second quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Dame Emma Natasha Walmsley DBE (born June 1969) is the chief executive officer (CEO) of GSK plc. [1] She succeeded Sir Andrew Witty, who retired in March 2017. [2] Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. [3] She grew up in Barrow-in-Furness, Cumbria, England.
For premium support please call: 800-290-4726 more ways to reach us